On 20 May, 3SBio announced an exclusive licensing agreement with Pfizer, granting Pfizer ex-China rights to develop, manufacture and commercialise its PD-1/VEGF bispecific antibody (BsAb) SSGJ-707, while retaining rights in its China homeland. Pfizer will cover all development and regulatory costs in licensed regions. 3SBio will receive USD 1.25 billion upfront, plus up to USD 4.8 billion in potential milestone payments and tiered royalties on net sales. SSGJ-707, developed using 3SBio’s proprietary CLF2 platform, is in Phase III trials in China for PD-L1-positive non-small cell lung cancer (NSCLC) and multiple Phase II studies, with IND clearance in the US.